Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 7/20 | 0.47 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 4/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934061 | 0.94 | TGM2 (0.49) | TGM2SLC15A1ITGB3ITGA2BLTA4H | |
| SCHEMBL4934993 | 0.94 | TGM2 (0.49) | TGM2SLC15A1ITGB3ITGA2BLTA4H | |
| SCHEMBL9825676 | 0.92 | TGM2 (0.47) | TGM2SLC15A1ITGB3ITGA2BLTA4H | |
| SCHEMBL9825692 | 0.90 | TGM2 (0.46) | TGM2LTA4HLAP3 | |
| SCHEMBL9825838 | 0.85 | TGM2 (0.41) | TGM2SLC15A1ITGB3ITGA2BALPI | |
| SCHEMBL9826376 | 0.84 | TGM2 (0.41) | TGM2LTA4HALPIPKMPTGS1 | |
| SCHEMBL4936405 | 0.84 | TGM2 (0.38) | TGM2SLC15A1ITGB3ITGA2BLTA4H | |
| SCHEMBL9825346 | 0.84 | TGM2 (0.38) | TGM2SLC15A1ITGB3ITGA2BLTA4H | |
| SCHEMBL9826320 | 0.84 | TGM2 (0.43) | TGM2TSHR | |
| SCHEMBL9826313 | 0.83 | TGM2 (0.42) | TGM2ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080299170-A1 | Medical Devices and Coatings Therefor | ASTON UNIVERSITY (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299170-A1 | Medical Devices and Coatings Therefor | F8, HABP2, TFPI | TGM2 16/4885SLC15A1 1960/4885ITGB3 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.